Agent Promising for Refractory Colon Cancer (CME/CE)
(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.
(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.